BRCA1 and BRCA2 Genetic Testing in India: Cost, Process & Clinical Significance
Written by: Dr. Ananya Sharma, Medical Geneticist | Medically Reviewed by: Dr. Rajesh Kumar, Oncologist | Last Updated: February 2026
Test Overview
- Sample Required: Blood (2-3 ml) or Saliva
- Fasting: Not required
- Turnaround Time: 4-5 weeks
- Base Cost: ₹15,000 (includes free home sample collection)
Overview of BRCA1/2 Genes and Cancer Risk
BRCA1 and BRCA2 are tumor suppressor genes that encode proteins involved in DNA repair. When these genes carry pathogenic mutations, the body's ability to repair damaged DNA is compromised, leading to an accumulation of genetic errors and an increased risk of certain cancers.
Women with BRCA mutations have a significantly elevated risk of breast cancer and ovarian cancer. Men with BRCA mutations face increased risks of prostate cancer, male breast cancer, and pancreatic cancer. Other associated cancers include melanoma and, in some cases, fallopian tube and peritoneal cancers.
Who Should Consider BRCA1/2 Testing?
Genetic testing for BRCA1/2 is recommended for individuals with a personal or family history suggestive of hereditary cancer. Specific clinical indications include:
- A known BRCA1/2 mutation in a family member
- Personal history of breast cancer diagnosed at age 45 or younger
- Bilateral breast cancer (cancer in both breasts)
- Multiple relatives with breast, ovarian, prostate, or pancreatic cancer
- Ashkenazi Jewish ancestry (higher prevalence of founder mutations)
- Male breast cancer at any age
It is strongly advised to consult a genetic counsellor before undergoing testing to understand the implications and limitations.
Inheritance Pattern and Risk Transmission
BRCA1/2 mutations are inherited in an autosomal dominant pattern. This means that each child of a carrier has a 50% chance of inheriting the mutation. Importantly, carrying a mutation does not guarantee cancer development; it significantly increases lifetime risk, which can be managed through enhanced surveillance and preventive strategies.
Associated Cancer Spectrum and Risk Estimates
The following table summarizes approximate lifetime risks for BRCA1 and BRCA2 carriers compared to the general population. These figures are based on large meta-analyses and should be interpreted with the guidance of a healthcare provider.
| Cancer Type | General Population Risk | BRCA1 Carrier Risk | BRCA2 Carrier Risk |
|---|---|---|---|
| Breast (Women) | ~12% | 65–72% | 45–69% |
| Ovarian | ~1.3% | 39–44% | 11–17% |
| Prostate | ~11% | ~15% | 20–25% |
| Pancreatic | ~1.5% | 1–3% | 2–5% |
Molecular Analysis: Next-Generation Sequencing (NGS) and Whole Exome Sequencing (WES)
At DNA Labs India, BRCA1/2 testing is performed using Next-Generation Sequencing (NGS), a high-throughput technology that enables comprehensive analysis of both genes for single nucleotide variants, insertions, deletions, and large rearrangements. In select cases, Whole Exome Sequencing (WES) may be employed to evaluate additional cancer susceptibility genes when clinically indicated. This approach ensures high analytical sensitivity and specificity, with results interpreted by board-certified molecular geneticists.
Test Process and Sample Collection
- Pre-test genetic counselling to discuss risks, benefits, and limitations.
- Sample collection: A simple blood draw (2–3 ml) or saliva sample can be collected at home or at a DNA Labs India center.
- Laboratory analysis: DNA is extracted and sequenced using NGS.
- Results are reviewed and a comprehensive report is generated, including variant classification and clinical recommendations.
- Post-test counselling is offered to explain results and discuss management options.
Turnaround Time: 4–5 weeks from sample receipt.
Result Interpretation and Clinical Action
Positive Result
- Indicates a pathogenic mutation in BRCA1 or BRCA2.
- Confirms elevated cancer risk, but not a certainty.
- Enables proactive measures: enhanced screening (MRI, mammography), risk-reducing medications, or prophylactic surgery.
- Family members may also benefit from targeted testing.
Negative Result
- No pathogenic mutation detected in the tested genes.
- Does not eliminate cancer risk entirely; risk remains at general population levels.
- If a familial mutation is known and not found, the result is considered a true negative.
Variant of Uncertain Significance (VUS)
- A genetic change with unclear clinical impact.
- Requires further family studies and reclassification over time.
- Genetic counselling is essential to interpret VUS results.
Cost and Turnaround Time
| Parameter | Details |
|---|---|
| Test Price | ₹15,000 |
| Turnaround Time | 4–5 weeks |
| Sample Type | Blood or Saliva |
| Home Collection | Free (available in major cities) |
How to Book the Test
Booking your BRCA1/2 test with DNA Labs India is simple:
- Call your nearest DNA Labs India center
- Or book online for free home sample collection
Contact Numbers (Major Cities):
Mumbai: (022)48937160 | Delhi: (011)40849842 | Hyderabad: (040)49171772 | Bangalore: (080)45684079
(Check our website for full city list)
Key Takeaways
- BRCA1/2 mutations significantly increase cancer risk for both men and women.
- Testing is recommended for high-risk individuals based on personal and family history.
- NGS-based analysis ensures accurate detection of mutations.
- Cost in India: ₹15,000 with 4–5 weeks turnaround and free home sample collection.
- Early detection and proactive management can improve outcomes.
FAQ – BRCA1 and BRCA2 Genetic Testing in India
Q1. What is the BRCA1/2 test used for?
It detects inherited mutations in BRCA1 and BRCA2 genes that increase the risk of breast, ovarian, prostate, pancreatic, and other cancers.
Q2. Who should get tested?
People with a family history of BRCA mutations, early-onset breast cancer (≤45 years), bilateral breast cancer, or multiple relatives with related cancers.
Q3. How much does the BRCA test cost in India?
₹15,000 with free home sample collection.
Q4. How long do results take?
4–5 weeks, delivered via email.
Q5. Can men take the BRCA test?
Yes. Men with BRCA mutations have higher risk of prostate cancer, male breast cancer, and pancreatic cancer.